US Metro Bancorp Announces First Quarter 2025 Results
US Metro Bancorp (OTCQX: USMT): US Metro Bancorp ('Bancorp') is a bank holding company, with a single subsidiary, US Metro Bank ('Bank'). On a consolidated basis, Bancorp earned $2.6 million in the first quarter of 2025, compared to $1.7 million in the fourth quarter of 2024. For the three months ending March 31, 2025, the consolidated Bancorp earned $2.6 million compared to $1.5 million for the three months ending March 31, 2024. On a year-to-date basis, Bancorp recorded an annualized return on average assets ('ROAA') of 0.73% and an annualized return on average equity ('ROAE') of 10.10%. With 16,520,000 shares outstanding, earnings per share ('EPS') for the first quarter of 2025 was $0.16 compared to $0.11 in the fourth quarter of 2024. For the three months ending March 31, 2025, EPS was $0.16 compared to $0.09 for the three months ending March 31, 2024. On March 31, 2025, Bancorp's book value per share was $6.29 compared to $5.87 a year earlier.
The Bank recorded on a year-to-date basis net interest income of $10.0 million compared to $8.1 million in the same period a year earlier. Net income of $2.9 million for the three months ending March 31, 2025, compares to $1.8 million reported for the same three months in 2024, a year over year increase of $1.1 million.
The Bank reported total assets of $1.417 billion as of March 31, 2025, representing a 9.4% increase compared to the reporting period ending March 31, 2024, and year over year loan growth of $123 million or 11.4%. Total Bank deposits ended the first quarter of 2025 at $1.236 billion, a $104 million or 9.1% increase from $1.134 billion on March 31, 2024.
Loan quality remains good with non-performing assets as a percentage of total assets of 0.92% on March 31, 2025, compared to 0.17% as of March 31, 2024. The Bank had no Other Real Estate Owned (OREO) on March 31, 2025. Allowance for credit losses (ACL) to gross loans was 1.20% as of March 31, 2025, compared to 1.21% as of March 31, 2024. The Bank recorded a $0.3 million provision for loan loss expense, for the three months ending March 31, 2025, compared to no provision recorded for the three months ending March 31, 2024.
'We are pleased with the performance in the first quarter of 2025 with improved ROAE, NIM and efficiency ratio while the Bank continued to grow in both loans and deposits. Additionally, during the first quarter, the Bank opened its newest branch in Lakewood, Washington, which has expanded our presence in the Seattle, Washington area. US Metro Bank is well positioned to handle any challenges that 2025 may present,' said CEO Dong Il Kim.
US Metro Bank is a California chartered, full service commercial bank headquartered in Garden Grove, California. The Bank opened for business on September 15, 2006, and offers deposit and loan products (including commercial real estate, commercial and industrial, mortgage, SBA and USDA loans), as well as related banking services to its customers.
This release contains forward-looking statements, including our expectations with respect to future events that are subject to various risks and uncertainties. Factors that could cause actual results to differ materially from management's projections, forecasts, estimates and expectations include: fluctuation in market rates of interest and loan and deposit pricing, adverse changes in the overall national economy as well as adverse economic conditions in our specific market areas, maintenance and development of well-established and valued client relationships and referral source relationships, and acquisition or loss of key production personnel. Other risks that can affect the Bank are detailed from time to time in our annual reports. We caution readers that the list of factors above is not exclusive. The forward-looking statements are made as of the date of this release, and we may not undertake steps to update the forward-looking statements to reflect the impact of any circumstances or events that arise after the date the forward-looking statements are made. In addition, our past results of operations are not necessarily indicative of future performance.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250425578749/en/
CONTACT: Jeremy Johnson
(714) 620-8888
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: BANKING PROFESSIONAL SERVICES FINANCE
SOURCE: US Metro Bancorp
Copyright Business Wire 2025.
PUB: 04/25/2025 09:04 PM/DISC: 04/25/2025 09:03 PM
http://www.businesswire.com/news/home/20250425578749/en
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
Cresco Labs Solid Q2 Performance and Debt Refinancing Strengthen Foundation for Long-Term Value Creation
CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (' Cresco Labs ' or the ' Company '), the industry leader in branded cannabis products with a portfolio of America's most popular brands and the operator of Sunnyside dispensaries, today released its financial and operating results for the second quarter ended June 30, 2025. All financial information presented in this release is reported in accordance with U.S. GAAP and in U.S. dollars, unless otherwise indicated, and is available on the Company's investor website, here. Second Quarter 2025 Highlights Second quarter revenue of $164 million. Second quarter operating cash flow of $9 million. Gross profit of $83 million. Adjusted gross profit 1 of $83 million; and an Adjusted gross margin 1 of 50.6% of revenue. SG&A of $51 million or 31.4% of revenue. Net loss of $14 million, includes non-cash impairment charges of $9 million related to California assets being considered held for sale. Second quarter Adjusted EBITDA 1 of $41 million and Adjusted EBITDA margin 1 of 25.0%. Retained the No. 1 share position in multiple billion dollar markets. 2 Management Commentary "In Q2, we delivered solid performance in line with guidance, maintained our market share in a highly competitive environment, and continued to drive cash flow through operational discipline. Crucially, we signed a commitment letter to refinance our debt with a new $325 million term loan. This milestone reinforces our balance sheet, preserves our equity value and creates financial flexibility for years to come. The improved structure and terms give us a stronger foundation to execute against both near-term priorities and long-term growth opportunities.' "The cannabis industry is entering a new phase, defined by consolidation and rationalization. We're seeing more opportunities for M&A in very productive states that will be incremental for Cresco. As previously stated, we're going to be opportunistic while staying patient and disciplined so we can invest in sustainable growth when the right opportunities arise. With our proven operating model, focused and productive footprint, and clean capital structure, we're built for this moment and are well-positioned to be a partner of choice as the industry consolidates.' Balance Sheet, Liquidity, and Other Financial Information As of June 30, 2025, current assets were $315 million, including cash and cash equivalents of $147 million. The Company had senior secured term loan debt, net of discount and issuance costs, of $354 million and a mortgage loan, net of discount and issuance costs of $18 million. Total shares on a fully converted basis to Subordinate Voting Shares were 483,444,948 as of June 30, 2025. 1 See "Non-GAAP Financial Measures" at the end of this press release for more information regarding the Company's use of non-GAAP financial measures. 2 According to Hoodie Analytics. Expand Conference Call and Webcast The Company will host a conference call and webcast to discuss its financial results on Thursday, August 7, 2025, at 8:30am Eastern Time (7:30am Central Time). The conference call may be accessed via webcast or by dialing 1-833-470-1428 (US Toll Free) or 1-404-975-4839 (US Local), providing access code 158138. Archived access to the webcast will be available for one year on Cresco Labs' investor website, here. Consolidated Financial Statements The financial information reported in this press release is based on unaudited management prepared financial statements for the quarter ended June 30, 2025. These financial statements have been prepared in accordance with U.S. GAAP. The Company expects to file its unaudited condensed interim consolidated financial statements for the quarter ended June 30, 2025, on SEDAR+ and EDGAR on or about August 7, 2025. Accordingly, such financial information may be subject to change. All financial information contained in this press release is qualified in its entirety with reference to such financial statements. While the Company does not expect there to be any material changes between the information contained in this press release and the consolidated financial statements it files on SEDAR+ and EDGAR, to the extent that the financial information contained in this press release is inconsistent with the information contained in the Company's financial statements, the financial information contained in this press release shall be deemed to be modified or superseded by the Company's filed financial statements. The making of a modifying or superseding statement shall not be deemed an admission, for any purposes, that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws. Further, the reader should refer to the additional disclosures in the Company's audited financial statements for the year ended December 31, 2024, filed on SEDAR+ and EDGAR. Cresco Labs references certain non-GAAP financial measures throughout this press release, which may not be comparable to similar measures presented by other issuers. Please see the 'Non-GAAP Financial Measures' section below for more detailed information. Non-GAAP Financial Measures This release reports its financial results in accordance with U.S. GAAP and includes certain non-GAAP financial measures that do not have standardized definitions under U.S. GAAP. The non-GAAP measures include: Earnings before interest, taxes, depreciation, and amortization ('EBITDA'); Adjusted EBITDA; Adjusted EBITDA margin; Adjusted gross profit; Adjusted gross profit margin; Adjusted selling, general, and administrative expenses ('Adjusted SG&A'), Adjusted SG&A margin; and Free Cash Flow are non-GAAP financial measures and do not have standardized definitions under U.S. GAAP. The Company defines these non-GAAP financial measures as follows: EBITDA as net loss (income) before interest, taxes, depreciation, and amortization; Adjusted EBITDA as EBITDA less other (expense) income, net, fair value mark-up for acquired inventory, adjustments for acquisition and non-core costs, impairment and share-based compensation; Adjusted EBITDA Margin as Adjusted EBITDA divided by revenues, net; Adjusted gross profit as gross profit less fair value mark-up for acquired inventory and adjustments for acquisition and non-core costs; Adjusted gross profit margin as Adjusted gross profit divided by revenues, net; Adjusted SG&A as SG&A less adjustments for acquisition and non-core costs; Adjusted SG&A margin as Adjusted SG&A divided by revenues, net; and Free Cash Flow as Net cash provided by operating activities less purchases of property and equipment and proceeds from tenant improvement allowances. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with U.S. GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with U.S. GAAP and may not be comparable to similar measures presented by other issuers. These supplemental non-GAAP financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the U.S. GAAP financial measures presented herein. Accordingly, the Company has included below reconciliations of the supplemental non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP. About Cresco Labs Inc. Cresco Labs' mission is to normalize and professionalize the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production, and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy's, and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development, and legislative initiatives designed to create the most responsible, respectable and robust cannabis industry possible. Learn more about Cresco Labs' journey by visiting or following the Company on Facebook, X or LinkedIn. Forward-Looking Statements This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute 'forward-looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, 'forward-looking statements'). Such forward-looking statements are not representative of historical facts or information or current condition but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as, 'may,' 'will,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'predicts,' 'potential,' or 'continue,' or the negative of those forms or other comparable terms. The Company's forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under 'Risk Factors' in the Company's Annual Information Form for the year ended December 31, 2024, filed on SEDAR+ and EDGAR, other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company's forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs' shares, nor as to the Company's financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company's forward-looking statements contained herein, whether as a result of new information, any future event, or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise. Cresco Labs Inc. Unaudited Reconciliation of Gross Profit to Adjusted Gross Profit (Non-GAAP) For the Three Months Ended June 30, 2025, March 31, 2025, and June 30, 2024 For the Three Months Ended ($ in thousands) June 30, 2025 March 31, 2025 June 30, 2024 Revenue, net $ 163,624 $ 165,757 $ 184,356 Cost of goods sold 1 80,368 87,126 89,578 Gross profit $ 83,256 $ 78,631 $ 94,778 Cost of goods sold adjustments for acquisition and other non-core costs (508 ) 3,144 1,881 Adjusted gross profit (Non-GAAP) $ 82,748 $ 81,775 $ 96,659 Adjusted gross profit % (Non-GAAP) 50.6 % 49.3 % 52.4 % 1 Production (cultivation, manufacturing, and processing) costs related to products sold during the period. Expand Cresco Labs Inc. Summarized Consolidated Statements of Financial Position As of June 30, 2025 and December 31, 2024 ($ in thousands) June 30, 2025 December 31, 2024 (unaudited) Cash and cash equivalents $ 146,609 $ 137,564 Other current assets 167,996 156,693 Property and equipment, net 332,600 344,846 Intangible assets, net 289,268 293,994 Goodwill 283,484 283,484 Other non-current assets 127,802 138,774 Total assets $ 1,347,759 $ 1,355,355 Total current liabilities $ 101,324 $ 94,338 Total non-current liabilities 885,523 872,841 Total shareholders' equity 360,912 388,176 Total liabilities and shareholders' equity $ 1,347,759 $ 1,355,355 Expand Cresco Labs Inc. Unaudited Reconciliation of SG&A to Adjusted SG&A (Non-GAAP) For the Three Months Ended June 30, 2025, March 31, 2025, and June 30, 2024 For the Three Months Ended ($ in thousands) June 30, 2025 March 31, 2025 June 30, 2024 Selling, general, and administrative $ 51,398 $ 57,811 $ 54,355 Adjustments for acquisition and other non-core costs 1,864 4,841 1,633 Adjusted SG&A (Non-GAAP) $ 49,534 $ 52,970 $ 52,722 Adjusted SG&A % (Non-GAAP) 30.3 % 32.0 % 28.6 % Expand Cresco Labs Inc. Unaudited Reconciliation of Net Loss to Adjusted EBITDA (Non-GAAP) For the Three Months Ended June 30, 2025, March 31, 2025, and June 30, 2024 For the Three Months Ended ($ in thousands) June 30, 2025 March 31, 2025 June 30, 2024 Net loss 1 $ (13,893 ) $ (15,234 ) $ (51,179 ) Depreciation and amortization 12,190 12,906 14,930 Interest expense, net 12,562 14,824 13,813 Income tax expense 16,636 14,316 10,238 EBITDA (Non-GAAP) $ 27,495 $ 26,812 $ (12,198 ) Other expense (income), net 836 (317 ) 59,508 Adjustments for acquisition and other non-core costs 734 7,015 3,129 Impairment loss 9,265 — — Share-based compensation 2,546 2,723 3,471 Adjusted EBITDA (Non-GAAP) $ 40,876 $ 36,233 $ 53,910 Adjusted EBITDA % (Non-GAAP) 25.0 % 21.9 % 29.2 % 1 Net loss includes amounts attributable to non-controlling interests. Expand Cresco Labs Inc. Unaudited Reconciliation of Operating Cash Flow to Free Cash Flow (Non-GAAP) For the Three Months Ended June 30, 2025, March 31, 2025, and June 30, 2024 For the Three Months Ended ($ in thousands) June 30, 2025 March 31, 2025 June 30, 2024 Net cash provided by operating activities $ 8,831 $ 30,463 $ 17,160 Purchases of property and equipment (13,124 ) (5,818 ) (6,434 ) Proceeds from tenant improvement allowances 451 50 106 Free Cash Flow (Non-GAAP) $ (3,842 ) $ 24,695 $ 10,832 Expand
Yahoo
an hour ago
- Yahoo
Trump tariff salvo sees India central bank return to out-of-favour rupee derivative tool
By Nimesh Vora MUMBAI, August 7 (Reuters) -The Reserve Bank of India has resumed intervention in the non-deliverable forwards market over the past fortnight to manage rupee volatility triggered by mounting trade tensions with the United States, four bankers told Reuters. This marks a return to a tool the central bank had largely refrained from using over the past seven months since Sanjay Malhotra took over as RBI governor and dialled back on currency intervention. The rupee has appeared increasingly vulnerable in recent weeks amid uncertainty over whether India will reach a trade deal with the U.S. The currency posted its largest weekly decline in nearly three years last Friday, weighed down by U.S. President Donald Trump's decision to impose steeper-than-expected 25% tariffs on Indian goods. The RBI stepped into the non-deliverable forward market last week, responding to the pressure on the currency, the bankers said. The strain on the rupee has persisted this week following Trump's warning of punitive action over India's continued imports of Russian oil, which culminated in an additional 25% tariff on Indian goods. The central bank may have stepped in this week too in the non-deliverable forward market, two out of the four bankers said. The rupee dropped to a six month low of 87.8850 versus the U.S. dollar on Tuesday, coming within a whisker of its all-time low of 87.95 hit in February. It would have likely breached that level if not for the Reserve Bank of India's intervention, traders said. As of 12:56 pm IST on Thursday, the currency was trading at 87.7275. An email to the RBI seeking comment did not draw an immediate response. The bankers spoke on condition of anonymity because they are not permitted to speak to the media. "The Trump tariff surprise and a possible all-time high (on dollar/rupee) brought the RBI back in NDF," head of FX and rates trading at a foreign bank said, "They're not going in heavy like previously, more of a light touch just to keep things in check." The RBI had largely stepped away from the non-deliverable forward market in recent months, significantly unwinding its positions, according to bankers. Under Malhotra the RBI has allowed higher volatility in the rupee, marking a shift from the tightly managed approach of his predecessor Shaktikanta Das. During Das's tenure, non-deliverable forwards had become RBI's preferred mode of intervention. Unlike onshore spot market operations, intervention through the non-deliverable forward market does not directly impact India's foreign exchange reserves or affect rupee liquidity in the domestic banking system. The RBI's intervention in the non-deliverable forwards market last week was complemented by sustained action in the onshore spot market, which contributed to a more than $9 billion decline in India's foreign exchange reserves. "The RBI is likely to be more aggressive in capping INR depreciation pressures given how far the currency has already cheapened over recent months in spot, NEER (nominal effective exchange rate) and REER (real effective exchange rate) terms," Singapore-based Mitul Kotecha, head of FX & EM Macro Strategy Asia at Barclays Bank, said in a note. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
an hour ago
- Bloomberg
Serbia Keeps Interest Rates Steady as Inflation Quickens Again
Serbia 's central bank kept interest rates unchanged for an 11th month with growing inflation risks taking precedence over weaker economic growth. The National Bank of Serbia held the one-week repurchase rate at 5.75% on Thursday, as predicted by most analysts in a Bloomberg survey. The decision followed a surge in the annual inflation rate to 4.6% in June, from 3.8% in May, breaching the upper end of the central bank's target range for the second time this year.
